Rosalind Franklin University of Medicine and Science
49Patents
46Active
49Granted
54Portfolio score
Filing activity: Nov 12, 2002 → Nov 21, 2022 · 8 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8753275B2 | Intelligent device to monitor and remind patients with footwear, walking aids, braces, or orthotics | Human Necessities | 28 | Active |
| US9840710B2 | Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease | Chemistry; Metallurgy | 5 | Active |
| US7780949B2 | Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases | Physics | 5 | Active |
| US9114112B2 | CCN3 and CCN3 peptides and analogs thereof for therapeutic uses | Chemistry; Metallurgy | 4 | Active |
| US9827478B1 | Providing visual motion feedback based on sensor data | Physics | 4 | Active |
| US9840709B2 | Antisense compounds targeting genes associated with cystic fibrosis | Chemistry; Metallurgy | 4 | Active |
| US7261887B2 | Leishmania as carriers for the delivery of proteins and peptides | Emerging Cross-Sectional Technologies | 4 | Expired |
| US10525076B2 | Antisense compounds targeting genes associated with cystic fibrosis | Chemistry; Metallurgy | 3 | Active |
| US10544417B2 | Antisense compounds targeting genes associated with cystic fibrosis | Chemistry; Metallurgy | 3 | Active |
| US7238347B2 | Suicidal mutant Leishmania vaccine | Emerging Cross-Sectional Technologies | 3 | Expired |
| US8518395B2 | CCN3 peptides and analogs thereof for therapeutic use | Chemistry; Metallurgy | 3 | Active |
| US8648053B2 | Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome | Chemistry; Metallurgy | 2 | Active |
| US10351608B2 | CCN3 and CCN3 peptides and analogs thereof for therapeutic use | Chemistry; Metallurgy | 2 | Active |
| US8133860B2 | Facilitation of resuscitation from cardiac arrest by erythropoietin | Human Necessities | 2 | Active |
| US10721993B2 | Intelligent offloading insole device | Physics | 2 | Active |
| US7956037B2 | Cytoprotective therapeutic agents for the prevention of reperfusion injury following ischemic stroke | Human Necessities | 2 | Active |
| US11732260B2 | Compounds and methods for the modulation of amyloid-β precursor protein | Chemistry; Metallurgy | 1 | Active |
| US9353371B2 | Antisense compounds targeting genes associated with usher syndrome | Chemistry; Metallurgy | 1 | Active |
| US9327017B2 | Leishmania-based carrier for vaccine delivery | Emerging Cross-Sectional Technologies | 1 | Active |
| US11505582B2 | CCN3 and CCN3 peptides and analogs thereof for therapeutic use | Chemistry; Metallurgy | 1 | Active |
| US8772468B2 | Splice variant specific messenger RNA transcripts as biomarkers of parkinson's disease | Chemistry; Metallurgy | 1 | Active |
| US11116785B2 | Antisense compounds targeting genes associated with cystic fibrosis | Chemistry; Metallurgy | 1 | Active |
| US8518886B2 | Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke | Human Necessities | 1 | Active |
| US12042508B2 | Antisense compounds targeting genes associated with cystic fibrosis | Chemistry; Metallurgy | 0 | Active |
| US8105257B2 | Extremity stress attenuation modality with resistance-mechanism engaging member | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.